BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

aTyr Pharma (ATYR)aTyr PharmaPartnership

Collaboration involves Company’s anti-NRP2 antibody ATYR2810 in preclinical studies of pediatric osteosarcoma. SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of

Related news

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

INMBINmune Bio2026-10-14 12:45 EST

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

IMMPImmutep Limited2026-10-14 12:00 EST

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

HCMHUTCHMED2026-10-21 00:00 EST

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

ATYRaTyr Pharma2026-10-13 12:00 EST

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

ATYRaTyr Pharma2026-09-24 10:00 EST

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

HCMHUTCHMED2026-09-03 04:00 EST

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

ATRAAtara Biotherapeutics, Inc.2026-09-30 12:05 EST

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

View all latest news

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

ATYRaTyr Pharma2026-10-19 11:00 EST

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

ATYRaTyr Pharma2026-10-13 12:00 EST

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

ATYRaTyr Pharma2026-09-24 10:00 EST

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-09-01 20:36 EST

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

ATYRaTyr Pharma2026-08-07 20:01 EST

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

Stock data

Close
0.17 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States